ORIGINAL RESEARCH ARTICLE
Thymoquinone enhances cisplatin-induced neprotoxicity in high dose
Received Date : 20 Oct 2015
Accepted Date : 09 Nov 2015
Ahmet Diricana, Osman Sahinb, Funda Taslic, Erkan Sogutd, Yuksel Kucukzeybeke, Ahmet Alacacioglue, Mustafa Gunesf,Gulcan Saglamd, Eyup Cobang, Mustafa Oktay Tarhanh, Buket Demircii
a Celal Bayar University Faculty of Medicine, Department of Medical Oncology, 45030 Manisa, Turkey
b Department of Nephrology, Faculty of Medicine, Recep Tayyip Erdogan University, Rize, Turkey
c Department of Medical Pathology, Medical Faculty, Sifa University, Izmir, Turkey
d Department of Biochemistry, Katip Celebi University of Medicine, Izmir, Turkey
e Department of Medical Oncology, Katip Celebi University of Medicine, Izmir, Turkey
f Department of Urology, Medical Faculty, Suleyman Demirel University, Isparta, Turkey
g Internal Medicine Ataturk Training and Research Hospital, Katip Celebi University, Izmir, Turkey
h Institute of Oncology, Dokuz Eylul University, Izmir, Turkey
iDepartment of Medical Pharmacology, Medical Faculty, Adnan Menderes University, Aydin, Turkey
Doi: 10.1016/j.jons.2015.11.005 - Article's Language: EN
Journal of Oncological Science 1 (2016) 17-24
ABSTRACT
Background: Cisplatin-induced nephrotoxicity is an important problem of the cancer treatments. The major bioactive component of Nigella sativa, thymoquinone (TQ) might limit the nephrotoxic effect of cisplatin in low doses. However, it is not clear how it can affect the kidney as an anti-cytotoxic agent when administered in higher doses or in cisplatin co-treatment. Therefore, we examined the in vivo interactions between cisplatin and TQ by measuring serum cystatin C (cys C), creatinine and neutrophil gelatinase-associated lipocalin (NGAL) levels and analyzing the expression status of p53 and NGAL by immunohistochemistry.
Methods: Wistar rats were divided into four groups: Control, TQ treatment (group II; 40 mg/kg i.p. for 5 days), cisplatin treatment (group III; 7 mg/kg, i.p. for at day 3) and TQ and cisplatin co-treatment (group IV). Results: Administration of 40 mg/kg TQ had no effect on serum kidney parameters. In cisplatin received group's serum creatinine level was insignificant, but serum Csy C and NGAL levels were significantly increased. All serum creatinine, NGAL and Cys C levels were increased in co-treatment of cisplatin and TQ. Additionally, in this group, renal tubular damage was found significantly higher than both control and only cisplatin-treated groups. The kidney immunohistochemistry staining of NGAL and p53 were significantly more intense in group IV rather than the others. Conclusions: This study showed that the administration of cisplatin and high dose of TQ act synergistically to produce nephrotoxicity and the involvement of apoptotic pathway and proximal tubule damage might be the leading cause of on this effect.
Keywords: Cisplatin, Nephrotoxicity, Thymoquinone, Apoptosis, Rat